Clinical Progress

An analysis of BNT-116's R&D progress and its clinical results presented at the 2023 SITC

22 November 2023
4 min read

BNT116 is an intravenously administered RNA-lipoplex therapeutic cancer vaccine comprising six RNAs each encoding a tumor-associated antigen (TAA) frequently expressed in non-small cell lung cancer (NSCLC). The preliminary results from patients with advanced unresectable or metastatic NSCLC (ECOG 0–2) receiving BNT116 monotherapy with optional addition of cemiplimab was reported in 2023 SITC Congress.

BNT-116's R&D Progress

BNT-116 is an RNA vaccine and therapeutic vaccine that is being developed by BioNTech SE. As an RNA vaccine, BNT-116 utilizes the genetic material of the virus or disease it is targeting to stimulate an immune response in the body. The drug is primarily focused on treating neoplasms and respiratory diseases. Its active indications include advanced lung non-small cell carcinoma and non-small cell lung cancer.

According to the Patsnap Synapse, the highest phase of development for BNT-116 is Phase 1/2, indicating that the drug has progressed to early-stage clinical trials. And the clinical trial areas for BNT-116 are primarily in the United States, Germany and Hungary. The key indication is Advanced Lung Non-Small Cell Carcinoma.

Detailed Clinical Result of BNT-116

The non-randomized, sequential assignment, open-label clinical trial (NCT05142189) was aimed to confirm the dose of BNT116 alone or as combination therapy with cemiplimab, docetaxel, and/or carboplatin/paclitaxel (21-day cycles). 

In this study, the first six BNT116 doses are administered once weekly during Cycles 1 and 2 and three-weekly from Cycle 3 onwards. The cohort reported here will confirm the dose of BNT116 as monotherapy. Cemiplimab may be added from cycle 3 if tumor samples exhibit PD-L1 expression (tumor proportion score ≥1%). Patients’ prior therapies must have included a PD-1/PD-L1 inhibitor, a platinum-based chemotherapy regimen as well as one other systemic therapy. The objectives are to determine safety (dose limiting toxicities [DLTs] in Cycle 1; treatment-emergent adverse events [TEAEs]), and clinical activity (RECIST v1.1). Tumor and blood samples will be used for biomarker analysis.

The result showed that as of 01 March 2023, 18 patients (median age 65 years) have received BNT116 in the reported cohort (n=13 monotherapy only; n=5 cemiplimab added after Cycle 3). Most (16/18 [89%]) had received ≥3 prior therapy lines. All patients experienced ≥1 TEAE, and most TEAEs were grade 1–2 (table 1). TEAEs (incidence rate ≥5%) include pyrexia (n=12 [67%], grade 1–3), chills (n=9 [50%], grade 1–2), and vomiting (n=5 [28%], grade 1–2). Pyrexia and chills were considered treatment-related TEAEs for BNT116. Serious TEAEs were observed in 5/18 (28%) patients (grade 2 pneumothorax [n=1] or pyrexia [n=1], grade 3 fatigue [n=1] or pneumonia [n=1], and grade 4 acute kidney injury [n=1]). The latter grade 4 TEAE occurred during safety follow-up after trial treatment termination and was considered as unrelated to treatment with IMP. No DLTs or deaths under treatment were observed. Ten of 18 patients were evaluable for clinical activity (n=5 monotherapy only; n=5 cemiplimab added after Cycle 3). Of these, 6/10 had stable disease and 4/10 had progressive disease. The median duration of disease control was 1.53 months.

It can be concluded that in this trial, BNT116 was generally well tolerated with an expected safety profile as monotherapy and in combination with cemiplimab. Updated safety and clinical activity data will be presented along with additional biomarker data (TAA expression, PD-L1 expression, cytokines, tumor markers).

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

Ionetix will supply Bayer with Actinium-225 (Ac-225), a therapeutic radioisotope
Latest Hotspot
3 min read
Ionetix will supply Bayer with Actinium-225 (Ac-225), a therapeutic radioisotope
22 November 2023
Ionetix Corporation has publicized that it has entered into a supply contract for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer.
Read →
Alpine Immune Sciences reveals new study results for Lupus treatment at 2023 Rheumatology Convergence
Latest Hotspot
3 min read
Alpine Immune Sciences reveals new study results for Lupus treatment at 2023 Rheumatology Convergence
22 November 2023
Alpine Immune Sciences unveils fresh Acazicolcept study results for Systemic Lupus Erythematosus at 2023 Rheumatology Convergence by American College.
Read →
Decoding LY-3410738: a comprehensive study of its R&D trends and its clinical results in 2023 AACR
Decoding LY-3410738: a comprehensive study of its R&D trends and its clinical results in 2023 AACR
20 November 2023
The phase 1 trial of LY3410738, a covalent mutant IDH inhibitor, in advanced IDH-mutant CCAs and other tumors was presented at the AACR Congress, paving the way for further outcome evaluation.
Read →
NImmune Biopharma released promising Phase 2 results for their lupus drug NIM-1324 at the 2023 ACR Convergence
Latest Hotspot
3 min read
NImmune Biopharma released promising Phase 2 results for their lupus drug NIM-1324 at the 2023 ACR Convergence
20 November 2023
NImmune Biopharma unveiled promising early human trial results for NIM-1324, a Phase 2 drug candidate for Systemic Lupus Erythematosus, at the 2023 American College of Rheumatology Convergence.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.